AMGX.F Stock Overview
A biopharmaceutical company, engages in the research and development of gene-based medical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
AnGes, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥0.36 |
| 52 Week High | JP¥0.56 |
| 52 Week Low | JP¥0.34 |
| Beta | 0.67 |
| 1 Month Change | -11.87% |
| 3 Month Change | -33.53% |
| 1 Year Change | n/a |
| 3 Year Change | -88.85% |
| 5 Year Change | n/a |
| Change since IPO | -94.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| AMGX.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -3.3% | -0.4% |
| 1Y | n/a | -2.7% | 24.8% |
Return vs Industry: Insufficient data to determine how AMGX.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how AMGX.F performed against the US Market.
Price Volatility
| AMGX.F volatility | |
|---|---|
| AMGX.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AMGX.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine AMGX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 145 | Ei Yamada | www.anges.co.jp |
AnGes, Inc., a biopharmaceutical company, engages in the research and development of gene-based medical products. Its lead product is Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy for the treatment of ischemic diseases. The company is also developing NF-kB Decoy Oligonucleotide, a nucleic acid medicine that suppresses inflammation for diseases, including low back pain; drugs for treating atopic dermatitis and asthma; medical devices for the prevention of vascular medicine; cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer; and DNA vaccines for high blood pressure through collaborative research agreement with Osaka University.
AnGes, Inc. Fundamentals Summary
| AMGX.F fundamental statistics | |
|---|---|
| Market cap | US$86.71m |
| Earnings (TTM) | -US$62.25m |
| Revenue (TTM) | US$3.31m |
26.2x
P/S Ratio-1.4x
P/E RatioIs AMGX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMGX.F income statement (TTM) | |
|---|---|
| Revenue | JP¥521.00m |
| Cost of Revenue | JP¥329.00m |
| Gross Profit | JP¥192.00m |
| Other Expenses | JP¥9.99b |
| Earnings | -JP¥9.79b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 07, 2025
| Earnings per share (EPS) | -35.90 |
| Gross Margin | 36.85% |
| Net Profit Margin | -1,880.04% |
| Debt/Equity Ratio | 5.9% |
How did AMGX.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 13:21 |
| End of Day Share Price | 2024/12/05 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AnGes, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kiyokazu Yamazaki | Ichiyoshi Research Institute Inc. |
| Toshiyuki Iwata | Mizuho Securities Co., Ltd. |
| Shinichiro Muraoka | Morgan Stanley |